Capivasertib
- Generic Name
- Capivasertib
- Brand Names
- Truqap
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25ClN6O2
- CAS Number
- 1143532-39-1
- Unique Ingredient Identifier
- WFR23M21IE
- Background
Capivasertib has been investigated for the treatment of Metastatic Breast Cancer.
- Associated Conditions
- -
- Associated Therapies
- -
Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients
- First Posted Date
- 2024-10-10
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 560
- Registration Number
- NCT06635447
- Locations
- 🇨🇳
Research Site, Zhengzhou, China
Effect of Capivasertib on ctDNA in ER Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-09-26
- Last Posted Date
- 2024-09-26
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 20
- Registration Number
- NCT06613516
- Locations
- 🇬🇧
Imperial College Healthcare Trust, London, United Kingdom
Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2024-09-23
- Lead Sponsor
- German Breast Group
- Target Recruit Count
- 120
- Registration Number
- NCT06607757
- Locations
- 🇩🇪
Charité, Berlin, Germany
Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC
- Conditions
- Interventions
- First Posted Date
- 2023-02-09
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 42
- Registration Number
- NCT05720260
- Locations
- 🇨🇳
Department of Oncology, National Taiwan University Hospital, Taipei City, Taiwan
A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss
- Conditions
- Interventions
- First Posted Date
- 2022-10-25
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 30
- Registration Number
- NCT05593497
- Locations
- 🇺🇸
VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California, United States
🇺🇸James J. Peters VA Medical Center, Bronx, NY, Bronx, New York, United States
🇺🇸VA Portland Health Care System, Portland, OR, Portland, Oregon, United States
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Stemline Therapeutics, Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT05563220
- Locations
- 🇩🇪
Universitaetsklinikum Mannheim, Mannheim, Baden-Wuerttemberg, Germany
🇺🇸Dothan Hematology and Oncology, Dothan, Alabama, United States
🇺🇸Mayo Clinic - Arizona, Phoenix, Arizona, United States
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
- Conditions
- Interventions
- First Posted Date
- 2022-04-27
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1017
- Registration Number
- NCT05348577
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
- Conditions
- Advanced Head and Neck Squamous Cell CarcinomaAdvanced Ovarian Clear Cell AdenocarcinomaChondrosarcomaClinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Pathologic Stage III Cutaneous Melanoma AJCC v8Pathologic Stage IIIA Cutaneous Melanoma AJCC v8Pathologic Stage IIIB Cutaneous Melanoma AJCC v8Pathologic Stage IIIC Cutaneous Melanoma AJCC v8Pathologic Stage IIID Cutaneous Melanoma AJCC v8
- Interventions
- First Posted Date
- 2021-09-10
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 54
- Registration Number
- NCT05039801
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-08-17
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT05008055
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid Tumours
- First Posted Date
- 2021-07-12
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 21
- Registration Number
- NCT04958226
- Locations
- 🇺🇸
Research Site, Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.